Written question asked by Crispin Blunt (Conservative) on Tuesday, 24 January 2023, in the House of Commons. It was due for an answer on Thursday, 26 January 2023. It was answered by Chris Philp (Conservative) on Wednesday, 1 February 2023 on behalf of the Home Office.
Psilocybin
- Question
-
To ask the Secretary of State for the Home Department, pursuant to the Answer of 24 October 2022 to Question 67096, on Psilocybin, and to the Answer of 23 January 2023 to Question 126511, on Psilocybin: Misuse, for what reason she will not conduct a review of the harms of psilocybin.
- Answer
-
Psilocybin, as an “ester of psilocin”, is controlled as a Class A drug under the Misuse of Drugs Act 1971 and has been since the Act was introduced. As set out in the response to Parliamentary Question 67096, the Government has no plans to commission the Advisory Council on the Misuse of Drugs to assess the classification of Psilocybin.
A review of classification is not currently a priority in the context of the significant challenges of drug misuse set out in Dame Carol Black's independent review of drugs, which the government is focused on tackling through the 10-year Drug Strategy, including work to improve treatment and recovery services, tackle drugs supply and reduce the demand for drugs in society.
Secondary information
- Type
- Written question
- Reference
- 131114
- Session
- 2022-23
- Related items
- Subjects
- Health hazards Misuse Psilocybin
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-02-01 16:29:39 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/131114
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/131114
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/131114